Autotaxin

Jan 23, 2020

iOnctura Raises EUR 15 Million in Series A Financing to Progress its Pipeline into Clinical Development

May 19, 2019

Bridge Biotherapeutics Announces Data Presentation from First-in-Human Study of BBT-877 for Idiopathic Pulmonary Fibrosis

Jan 16, 2019

Bridge Biotherapeutics Announces FDA Orphan Drug Designation for BBT-877 in Idiopathic Pulmonary Fibrosis (IPF)

Dec 27, 2018

Bridge Biotherapeutics Announces a Successful Activation of U.S. Clinical Trial Sites for BBT-401 Phase 2 Study

Dec 16, 2018

Bridge Biotherapeutics Announces FDA Clearance of IND for its BBT-877, an Autotaxin Inhibitor for IPF

Nov 18, 2018

Bridge Biotherapeutics Files Investigational New Drug Application for BBT-877, an Autotaxin Inhibitor for Idiopathic Pulmonary Fibrosis

Nov 12, 2018

The First Pellino-1 Inhibitor BBT-401 Confirms Its Safety and Tolerability from the Phase I Study

Aug 22, 2018

Bridge Biotherapeutics Presented Preclinical Study Results on BBT-877, an Autotaxin inhibitor at the IPF Summit 2018

Aug 22, 2017

PharmAkea Announces Successful Completion of a Phase 1 Trial in Healthy Subjects For Its Novel LOXL2 Inhibitor, PAT-1251